Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
7.30
-0.47 (-6.05%)
At close: Oct 10, 2025, 4:00 PM EDT
7.46
+0.16 (2.19%)
After-hours: Oct 10, 2025, 4:10 PM EDT
Tenax Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
291.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Apr 30, 2015 | 49.29K | -135.37K | -73.31% |
| Apr 30, 2014 | 184.66K | -1.10M | -85.61% |
| Apr 30, 2013 | 1.28M | 819.31K | 176.46% |
| Apr 30, 2012 | 464.30K | 38.78K | 9.11% |
| Apr 30, 2011 | 425.52K | 369.78K | 663.41% |
| Apr 30, 2010 | 55.74K | - | - |
| Apr 30, 2009 | - | - | - |
| Apr 30, 2008 | - | - | - |
| Apr 30, 2007 | - | - | - |
| Apr 30, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TENX News
- 24 days ago - Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF - GlobeNewsWire
- 6 weeks ago - Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 2 months ago - Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha
- 6 months ago - Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 months ago - Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewsWire